A Study to Evaluate the Efficacy and Safety of CnU Capsule 750 mg in Patients With Cholesterol Gallstones(GB Stones).

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE4

Total Enrollment

484 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-07-28

Study Completion Date

2026-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this clinical trial is to evaluate the efficacy and safety of CnU capsule 750 mg administration in patients with Cholesterol gallstone (radiolucent gallstones)

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study to Evaluate Efficacy and Safety of PENNEL Capsule in the Patients With Chronic Liver Disease

NCT01393678

Chronic Liver Disease

COMPLETED PHASE3

Study to Evaluate Efficacy, Safety and Tolerability of PENNEL Capsule in the Patients With Chronic Liver Disease

NCT01393665

Chronic Liver Disease

COMPLETED PHASE2

Clinical Trial to Evaluate the Efficacy and Safety of 'URSA SOFT CAP. (UDCA-003)' in Fatigue Patients With Liver Dysfunction

NCT02415777

Fatigue

COMPLETED PHASE4

A Trial of 18-22mg/kg/d Ursodeoxycholic in Refractory Primary Biliary Cholangitis

NCT03345589

Primary Biliary Cholangitis

UNKNOWN PHASE4

A Strategy for Gallstone Expulsion Through Dietary Therapy

NCT06699030

Gallbladder Stone

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cholesterol Cholelithiasis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CnU capsule 250 mg(1 capsule) and Ursa placebo tablet 200 mg(1 tablet)

Group Type EXPERIMENTAL

CnU cap. 250mg & Ursa placebo tab. 200mg

Intervention Type DRUG

CnU capsule(Magnesium Salt Trihydrate of Chenodeoxycholic Acid and Ursodeoxycholic Acid) and Ursa placebo tablet will be orally administered three times a day after meals at regular intervals for a total of 24 weeks.

Ursa tablet 200 mg(1 tablet) and CnU placebo capsule 250 mg(1 capsule)

Group Type ACTIVE_COMPARATOR

Ursa tab. 200mg & CnU placebo cap. 250mg

Intervention Type DRUG

Ursa tablet(Ursodeoxycholic Acid) and CnU placebo capsule will be orally administered three times a day after meals at regular intervals for a total of 24 weeks.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CnU cap. 250mg & Ursa placebo tab. 200mg

CnU capsule(Magnesium Salt Trihydrate of Chenodeoxycholic Acid and Ursodeoxycholic Acid) and Ursa placebo tablet will be orally administered three times a day after meals at regular intervals for a total of 24 weeks.

Intervention Type DRUG

Ursa tab. 200mg & CnU placebo cap. 250mg

Ursa tablet(Ursodeoxycholic Acid) and CnU placebo capsule will be orally administered three times a day after meals at regular intervals for a total of 24 weeks.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Individuals who have voluntarily agreed to participate in this clinical trial
2. Adults aged 19 years and older
3. Individuals diagnosed with gall bladder stone(GB stone) with a maximum diameter size of 15 mm or less, as determined by abdominal ultrasonography at the screening stage, and who have radiolucent GB stones on plain abdominal X-ray

Exclusion Criteria

1\. Medical History

1. Patients with frequent biliary colic or biliary infections (severe pancreatic changes, such as ileal resection, resection surgery, or partial ileitis, may alter the composition of bile acids circulating in the intestines).
2. Patients with obstructive jaundice.
3. Patients with liver disease.
4. Patients with severe kidney disease.
5. Patients with severe biliary obstruction (due to choleretic effects, symptoms may worsen).
6. Patients with underlying diseases that could worsen biliary obstruction (such as biliary cancer, cholangitis, or biliary cysts).
7. Patients with acute cholecystitis.
8. Patients with peptic ulcers (due to mucosal irritation, symptoms may worsen).
9. Patients with inflammatory bowel diseases, such as Crohn's disease.
10. Patients with cholestasis.
11. Patients with abnormal gallbladder contraction.
12. Individuals with a history of malignant tumors within 5 years prior to the screening stage.
13. Individuals with a history of gastrointestinal surgery.
14. Individuals known to have hypersensitivity to the ingredients or additives of the clinical trial drug.
15. Individuals showing clinically significant disorders in the cardiovascular, gastrointestinal, respiratory, endocrine, or central nervous systems, or individuals who have had or currently have a mental disorder that could significantly affect this clinical trial.
16. Individuals with drug or alcohol addiction.
17. Individuals with genetic disorders such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.

2\. Individuals showing abnormal test results at the screening stage:

1. BMI ≥ 35 kg/m².
2. ALT or AST \> 2.0 x ULN.
3. Total bilirubin \> 2.0 x ULN.
4. eGFR \< 60 mL/min/1.73 m² (CKD-EPI formula).
5. Positive results in serum tests (HBsAg, HCV Ab, HIV Ab, Syphilis reagin test).

3\. Contraindicated drugs and therapies

The following drugs may be used after a washout period and registration:

1. Medications that increase bile secretion within 1 week prior to screening (e.g., estrogen, hormonal contraceptives, some lipid-lowering agents), or medications that reduce blood cholesterol (e.g., clofibrate).
2. Medications containing cholestyramine, colestipol, activated charcoal, magnesium, or aluminum hydroxide antacids within 2 weeks prior to screening.
3. Oral bile acid dissolution agents within 4 weeks prior to screening (e.g., chenodeoxycholic acid (CDCA), ursodeoxycholic acid (UDCA), HMG-CoA reductase inhibitors, Terpene).
4. Oral anti-diabetic medications (e.g., tolbutamide).
5. Individuals who have received bile acid treatment within 4 weeks prior to screening.

The following drugs cannot be used regardless of the washout period: Alpha-methyldopa.

4\. Pregnant and breastfeeding women

5\. Contraception

Participants and their spouses (or partners) who do not use medically acceptable contraceptive methods throughout the clinical trial period:

1. Use of intrauterine devices (IUD) or intrauterine systems (IUS) with proven failure rates of pregnancy.
2. Use of dual barrier contraception (male condom and cervical cap: contraceptive vaginal diaphragm or cervical cap) combined with spermicides.
3. Sterilization procedures (vasectomy, tubal ligation or cauterization, hysterectomy).

6\. Other individuals deemed inappropriate for participation in the clinical trial by the investigator.

Minimum Eligible Age

19 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No